Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

NCT04785924 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of enrollment

Conditions

Carbapenem-Resistant Enterobacteriaceae Infection
KPC
Gram-Negative Bacterial Infections
Antibiotic Resistant Infection

Interventions

DRUG: Imipenem+Relebactam

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]